Duphalac

SUMMARY OF PRODUCT CHARACTERISTICS
2.
NAME OF THE MEDICINAL PRODUCT
Duphalac
QUALITATIVE AND QUANTITATIVE COMPOSITION

Lactulose 3.335 g/5 ml.
3.
PHARMACEUTICAL FORM
Oral solution.
A clear or not more than slightly opalescent, viscous liquid, colourless to brownish
yellow.
4.1
Therapeutic indications
1. For the treatment of constipation.
2. For the treatment of hepatic encephalopathy (HE); hepatic coma.
4.2
Posology and method of administration

The lactulose solution may be administered diluted or undiluted. Each dose may if
necessary be taken with water or fruit juices, etc.
Each dose of lactulose should be swallowed in one and should not be kept in the mouth
for an extended period of time.
The posology should be adjusted according to the individual needs of the patient.
In case of single daily dose, this should be taken at the same time, e.g. during
breakfast.
During the therapy with laxatives it is recommended to drink sufficient amounts of
fluids (1.52 litres, equal to 6-8 glasses) during the day.
For lactulose in bottles the measuring cup may be used.
For lactulose in 15 ml single dose sachets the corner of the sachet should be torn off
and contents taken immediately.
Dosing in constipation:
Lactulose may be given as a single daily dose or in two divided doses, for lactulose in
bottles the measuring cup may be used.
After a few days the starting dosage may be adjusted to the maintenance dose based
upon treatment response. Several days (2-3 days) of treatment may be needed before
treatment effect occurs.
Lactulose oral solution in bottles or 15 ml single dose sachets:
Adults and adolescents
Children
(7-14 years)
Starting dose
daily
15-45 ml,
corresponding to
1-3 sachets
15 ml, corresponding to
1 sachet
Maintenance dose
daily
15-30 ml,
corresponding to
1-2 sachets
10-15 ml,
corresponding to
1 sachet*
5-10 ml
Children
5-10 ml
(1-6 years)
Infants under 1 year
up to 5 ml
up to 5 ml
* If the maintenance dose is below 15 ml, lactulose in bottles should be used.
For a precise dosing for infants and children up to 7 years lactulose in bottles should
be used.
Dosing in HE (for adults only):
Starting dose: 3 to 4 times daily 30-45 ml (6-9 x 5 ml spoonfuls) or 2-3 sachets. This
dose may be adjusted to the maintenance dose to achieve two or three soft stools each
day.
Paediatric population
The safety and efficacy in children (newborn to 18 years of age) with HE have not
been established. No data are available.
Elderly patients and patients with renal or hepatic insufficiency
No special dosage recommendations exist, since systemic exposure to lactulose is
negligible.
4.3
Contraindications
4.4
Hypersensitivity to the active substance or any of the ingredients.

Galactosaemia.
Gastro-intestinal obstruction, digestive perforation or risk of digestive perforation.
Special warnings and special precautions for use

Consultation of a physician is advised in case of:
Painful abdominal symptoms of undetermined cause before the treatment is
started.
Insufficient therapeutic effect after several days.
Lactulose should be administered with care to patients who are intolerant to lactose (see
section List of excipients).
The dose normally used in constipation should not pose a problem for diabetics.
The dose used in the treatment of HE is usually much higher and may need to be taken
into consideration for diabetics.
Chronic use of unadjusted doses and misuse can lead to diarrhoea and disturbance of the
electrolyte balance.
This product contains lactose, galactose and small amounts of fructose. Patients with rare
hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicine.
Use of laxatives in children should be exceptional and under medical supervision.
It should be taken into account that the defaecation reflex could be disturbed during the
treatment.
4.5
Interactions with other medicinal products and other forms of interaction

None known.
4.6
Pregnancy and lactation

Pregnancy
No effects during pregnancy are anticipated, since systemic exposure to lactulose is
negligible.
Duphalac can be used during pregnancy.
Lactation
No effects on the breastfed newborn/infant are anticipated since the systemic
exposure of the breast-feeding woman to lactulose is negligible.
Duphalac can be used during breast-feeding.
Fertility
No effects are to be expected, since systemic exposure to lactulose is negligible.
4.7.
Effects on ability to drive and use machines

Lactulose has no or negligible influence on the ability to drive and use machines
4.8
Undesirable effects
Flatulence may occur during the first few days of treatment. As a rule it disappears
after a couple of days. When dosages higher than instructed are used, abdominal pain
and diarrhoea may occur. In such a case the dosage should be decreased. See also
overdose section 4.9.
If high doses (normally only associated with hepatic encephalopathy, HE) are used
for an extended period of time, the patient may experience an electrolyte imbalance
due to diarrhoea. Dosage should then be adjusted to obtain two or three formed stools
per day.
Tabulated list of adverse reactions
The following undesirable effects have been experienced with the below indicated
frequencies in lactulose-treated patients in placebo-controlled clinical trials:
very common (1/10);

common (1/100 to <1/10);
uncommon (1/1,000 to <1/100);
rare (1/10,000 to <1/1,000);
very rare (<1/10,000)].
MedDRA SOC
Gastrointestinal
disorders
Frequency category
Very
Common
common
Diarrhoea Flatulence,
abdominal
pain, nausea,
vomiting
Investigations
Uncommon
Rare
Electrolyte
imbalance
due to
diarrhoea
The safety profile in children is expected to be similar as in adults.
Reporting of suspected adverse reactions
Reporting of suspected adverse reactions is an important way to gather more
information to continuously monitor the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the
MHRA Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard
4.9
Overdose
If the dose is too high, the following may occur:
Symptom: diarrhoea and abdominal pain.
Treatment: cessation of treatment or dose reduction. Extensive fluid loss by diarrhoea
or vomiting may require correction of electrolyte disturbances.
No specific antidote. Symptomatic treatment should be given.
5.1
Pharmacodynamic properties
Pharmacotherapeutic group: Osmotically acting laxatives, ATC code: A 06A D11
In the colon lactulose is broken down by colonic bacteria into low molecular organic
acids. These acids lead to a lowering of pH in the colonic lumen and via an osmotic
effect to an increase of the volume of colonic contents. These effects stimulate
peristalsis of the colon and return the consistency of the stool. The constipation is
cleared and the physiological rhythm of the colon is reinstated.
In hepatic encephalopathy (HE) the effect has been attributed to suppression of
proteolytic bacteria by an increase of acidophilic bacteria (e.g. lactobacillus), trapping
of ammonia in the ionic form by acidification of the colonic contents, catharsis due to
the low pH in the colon as well as an osmotic effect, and alteration of the bacterial
nitrogen metabolism by stimulating the bacteria to utilize ammonia for bacterial

protein synthesis.
5.2
Pharmacokinetic Properties
Lactulose is poorly absorbed after oral administration and it reaches the colon
unchanged. There it is metabolised by the colonic bacterial flora. Metabolism is
complete at doses up to 25-50 g or 40-75 ml; at higher dosages, a proportion may be
excreted unchanged.
5.3
Preclinical safety data

The results of acute, sub-chronic and chronic toxicity studies in various species
indicate that the compound has very low toxicity. The effects observed, appear to be
more related to the effect of bulk in the gastrointestinal tract than to a more specific
toxic activity. In reproduction and teratology experiments in rabbits, rats or mice no
adverse effects were found.
6.
PHARMACEUTICAL PARTICULARS
6.1
List of excipients
None.
6.2
Incompatibilities
None known.
6.3
Shelf life
HDPE: 2 years. Other containers: 3 years.
6.4
Special precautions for storage

Do not store above 25C. Do not refrigerate or freeze.
6.5
Nature and contents of container

Brown glass and white HDPE bottles containing 200, 300, 500 and 1000 ml;
polyethylene bottles containing 5 litres; 15 ml foil sachets.
6.6
Instructions for use/handling

None.
MARKETING AUTHORISATION HOLDER
Abbott Healthcare Products Ltd.

Mansbridge Road
West End
Southampton
SO18 3JD
8.
MARKETING AUTHORISATION NUMBER(S)

PL 00512/5001R
9.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
14.03.88 / 23.07.99
10
DATE OF REVISION OF THE TEXT

13/11/2014

Duphalac

Uploaded by

Copyright:

Available Formats

Duphalac

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Duphalac

Uploaded by

Copyright:

Available Formats

SUMMARY OF PRODUCT CHARACTERISTICS

NAME OF THE MEDICINAL PRODUCT

QUALITATIVE AND QUANTITATIVE COMPOSITION

Posology and method of administration

Adults and adolescents

Hypersensitivity to the active substance or any of the ingredients.

Special warnings and special precautions for use

Interactions with other medicinal products and other forms of interaction

Pregnancy and lactation

Effects on ability to drive and use machines

very common (1/10);

nitrogen metabolism by stimulating the bacteria to utilize ammonia for bacterial

Preclinical safety data

Special precautions for storage

Nature and contents of container

Instructions for use/handling

MARKETING AUTHORISATION HOLDER

Abbott Healthcare Products Ltd.

MARKETING AUTHORISATION NUMBER(S)

DATE OF REVISION OF THE TEXT

You might also like